Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy

Didier Cowen, Patricia Troncoso, Vincent S. Khoo, Gunar K. Zagars, Andrew C. Von Eschenbach, Marvin L. Meistrich, Alan Pollack

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Purpose: To determine the significance of Ki-67/MIB1 staining as a marker of patient outcome for prostate cancer patients treated with radiotherapy. Experimental Design: Pretreatment archival prostate biopsy tumor tissue was available from 106 stage T1-T4 prostate cancer patients treated with external beam radiotherapy between 1987 and 1993 at M. D. Anderson Cancer Center. Diagnosis was made from prostate needle biopsy in 64 cases and from transurethral resection of the prostate (TURP) in 42 cases. All patients had a pretreatment prostate-specific antigen (PSA), and no patient had evidence of metastasis. Immunohistochemical staining for MIB1 was used to determine the percentage of Ki-67-positive tumor cells, the Ki-67 labeling index (Ki67-LI). Biochemical failure after radiotherapy was defined as three rises in PSA on follow-up. Median follow-up was 62 months. Results: The mean and median Ki67-LI for the entire cohort was 3.2 and 2.3. The mean and median Ki67-LIs for those diagnosed by needle biopsy were 3.2 and 2.3, and by TURP were 3.1 and 2.4. For all patients, mean Ki67-LI levels were significantly higher with stage T3/T4 disease, Gleason 7-10 disease, and in those that developed treatment failure. Similar relationships were observed when the Ki67-LI was dichotomized into low (≤3.5%) and high (>3.5%) groups. Actuarial freedom from biochemical failure (bNED) when Ki67-LI was low and high was 76 and 33% at 5 years (P < 0.0001, log rank). Similar statistically significant differences were observed when the TURP and needle biopsy groups were analyzed separately. Cox proportional hazards regression showed that dichotomized Ki67-LI was an independent correlate of bNED, along with pretreatment PSA, Gleason score, and clinical stage. Conclusions: The Ki67-LI obtained from pretreatment prostate cancer tissue is a strong independent predictor of failure after radiotherapy using biochemical criteria. This prognostic factor was equally valuable for patients diagnosed by TURP or needle biopsy.

Original languageEnglish
Pages (from-to)1148-1154
Number of pages7
JournalClinical Cancer Research
Volume8
Issue number5
StatePublished - May 27 2002
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Radiotherapy
Transurethral Resection of Prostate
Staining and Labeling
Needle Biopsy
Prostate-Specific Antigen
Prostate
Neoplasms
Neoplasm Grading
Treatment Failure
Research Design
Neoplasm Metastasis
Biopsy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cowen, D., Troncoso, P., Khoo, V. S., Zagars, G. K., Von Eschenbach, A. C., Meistrich, M. L., & Pollack, A. (2002). Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clinical Cancer Research, 8(5), 1148-1154.

Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. / Cowen, Didier; Troncoso, Patricia; Khoo, Vincent S.; Zagars, Gunar K.; Von Eschenbach, Andrew C.; Meistrich, Marvin L.; Pollack, Alan.

In: Clinical Cancer Research, Vol. 8, No. 5, 27.05.2002, p. 1148-1154.

Research output: Contribution to journalArticle

Cowen, D, Troncoso, P, Khoo, VS, Zagars, GK, Von Eschenbach, AC, Meistrich, ML & Pollack, A 2002, 'Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy', Clinical Cancer Research, vol. 8, no. 5, pp. 1148-1154.
Cowen D, Troncoso P, Khoo VS, Zagars GK, Von Eschenbach AC, Meistrich ML et al. Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. Clinical Cancer Research. 2002 May 27;8(5):1148-1154.
Cowen, Didier ; Troncoso, Patricia ; Khoo, Vincent S. ; Zagars, Gunar K. ; Von Eschenbach, Andrew C. ; Meistrich, Marvin L. ; Pollack, Alan. / Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy. In: Clinical Cancer Research. 2002 ; Vol. 8, No. 5. pp. 1148-1154.
@article{ffbcba4d51ec46edb33b043f9437d527,
title = "Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy",
abstract = "Purpose: To determine the significance of Ki-67/MIB1 staining as a marker of patient outcome for prostate cancer patients treated with radiotherapy. Experimental Design: Pretreatment archival prostate biopsy tumor tissue was available from 106 stage T1-T4 prostate cancer patients treated with external beam radiotherapy between 1987 and 1993 at M. D. Anderson Cancer Center. Diagnosis was made from prostate needle biopsy in 64 cases and from transurethral resection of the prostate (TURP) in 42 cases. All patients had a pretreatment prostate-specific antigen (PSA), and no patient had evidence of metastasis. Immunohistochemical staining for MIB1 was used to determine the percentage of Ki-67-positive tumor cells, the Ki-67 labeling index (Ki67-LI). Biochemical failure after radiotherapy was defined as three rises in PSA on follow-up. Median follow-up was 62 months. Results: The mean and median Ki67-LI for the entire cohort was 3.2 and 2.3. The mean and median Ki67-LIs for those diagnosed by needle biopsy were 3.2 and 2.3, and by TURP were 3.1 and 2.4. For all patients, mean Ki67-LI levels were significantly higher with stage T3/T4 disease, Gleason 7-10 disease, and in those that developed treatment failure. Similar relationships were observed when the Ki67-LI was dichotomized into low (≤3.5{\%}) and high (>3.5{\%}) groups. Actuarial freedom from biochemical failure (bNED) when Ki67-LI was low and high was 76 and 33{\%} at 5 years (P < 0.0001, log rank). Similar statistically significant differences were observed when the TURP and needle biopsy groups were analyzed separately. Cox proportional hazards regression showed that dichotomized Ki67-LI was an independent correlate of bNED, along with pretreatment PSA, Gleason score, and clinical stage. Conclusions: The Ki67-LI obtained from pretreatment prostate cancer tissue is a strong independent predictor of failure after radiotherapy using biochemical criteria. This prognostic factor was equally valuable for patients diagnosed by TURP or needle biopsy.",
author = "Didier Cowen and Patricia Troncoso and Khoo, {Vincent S.} and Zagars, {Gunar K.} and {Von Eschenbach}, {Andrew C.} and Meistrich, {Marvin L.} and Alan Pollack",
year = "2002",
month = "5",
day = "27",
language = "English",
volume = "8",
pages = "1148--1154",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy

AU - Cowen, Didier

AU - Troncoso, Patricia

AU - Khoo, Vincent S.

AU - Zagars, Gunar K.

AU - Von Eschenbach, Andrew C.

AU - Meistrich, Marvin L.

AU - Pollack, Alan

PY - 2002/5/27

Y1 - 2002/5/27

N2 - Purpose: To determine the significance of Ki-67/MIB1 staining as a marker of patient outcome for prostate cancer patients treated with radiotherapy. Experimental Design: Pretreatment archival prostate biopsy tumor tissue was available from 106 stage T1-T4 prostate cancer patients treated with external beam radiotherapy between 1987 and 1993 at M. D. Anderson Cancer Center. Diagnosis was made from prostate needle biopsy in 64 cases and from transurethral resection of the prostate (TURP) in 42 cases. All patients had a pretreatment prostate-specific antigen (PSA), and no patient had evidence of metastasis. Immunohistochemical staining for MIB1 was used to determine the percentage of Ki-67-positive tumor cells, the Ki-67 labeling index (Ki67-LI). Biochemical failure after radiotherapy was defined as three rises in PSA on follow-up. Median follow-up was 62 months. Results: The mean and median Ki67-LI for the entire cohort was 3.2 and 2.3. The mean and median Ki67-LIs for those diagnosed by needle biopsy were 3.2 and 2.3, and by TURP were 3.1 and 2.4. For all patients, mean Ki67-LI levels were significantly higher with stage T3/T4 disease, Gleason 7-10 disease, and in those that developed treatment failure. Similar relationships were observed when the Ki67-LI was dichotomized into low (≤3.5%) and high (>3.5%) groups. Actuarial freedom from biochemical failure (bNED) when Ki67-LI was low and high was 76 and 33% at 5 years (P < 0.0001, log rank). Similar statistically significant differences were observed when the TURP and needle biopsy groups were analyzed separately. Cox proportional hazards regression showed that dichotomized Ki67-LI was an independent correlate of bNED, along with pretreatment PSA, Gleason score, and clinical stage. Conclusions: The Ki67-LI obtained from pretreatment prostate cancer tissue is a strong independent predictor of failure after radiotherapy using biochemical criteria. This prognostic factor was equally valuable for patients diagnosed by TURP or needle biopsy.

AB - Purpose: To determine the significance of Ki-67/MIB1 staining as a marker of patient outcome for prostate cancer patients treated with radiotherapy. Experimental Design: Pretreatment archival prostate biopsy tumor tissue was available from 106 stage T1-T4 prostate cancer patients treated with external beam radiotherapy between 1987 and 1993 at M. D. Anderson Cancer Center. Diagnosis was made from prostate needle biopsy in 64 cases and from transurethral resection of the prostate (TURP) in 42 cases. All patients had a pretreatment prostate-specific antigen (PSA), and no patient had evidence of metastasis. Immunohistochemical staining for MIB1 was used to determine the percentage of Ki-67-positive tumor cells, the Ki-67 labeling index (Ki67-LI). Biochemical failure after radiotherapy was defined as three rises in PSA on follow-up. Median follow-up was 62 months. Results: The mean and median Ki67-LI for the entire cohort was 3.2 and 2.3. The mean and median Ki67-LIs for those diagnosed by needle biopsy were 3.2 and 2.3, and by TURP were 3.1 and 2.4. For all patients, mean Ki67-LI levels were significantly higher with stage T3/T4 disease, Gleason 7-10 disease, and in those that developed treatment failure. Similar relationships were observed when the Ki67-LI was dichotomized into low (≤3.5%) and high (>3.5%) groups. Actuarial freedom from biochemical failure (bNED) when Ki67-LI was low and high was 76 and 33% at 5 years (P < 0.0001, log rank). Similar statistically significant differences were observed when the TURP and needle biopsy groups were analyzed separately. Cox proportional hazards regression showed that dichotomized Ki67-LI was an independent correlate of bNED, along with pretreatment PSA, Gleason score, and clinical stage. Conclusions: The Ki67-LI obtained from pretreatment prostate cancer tissue is a strong independent predictor of failure after radiotherapy using biochemical criteria. This prognostic factor was equally valuable for patients diagnosed by TURP or needle biopsy.

UR - http://www.scopus.com/inward/record.url?scp=0036096949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036096949&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 1148

EP - 1154

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -